Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | RHEB | Q15382 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19968181 | 0.87 | TLR7 (0.44) | — | |
| SCHEMBL28757935 | 0.86 | F10 (0.38) | CYP3A4GRM4DYRK1AP2RY14MEN1 | |
| SCHEMBL311172 | 0.83 | TP53 (0.38) | CYP3A4MAOBGRM4DYRK1AMEN1 | |
| SCHEMBL1232902 | 0.81 | DYRK1A (0.40) | DYRK1A | |
| SCHEMBL2059219 | 0.81 | BRD4 (0.44) | CYP3A4GRM4CYP2D6CYP2C9KIT | |
| SCHEMBL1231939 | 0.81 | DYRK1A (0.45) | DYRK1A | |
| SCHEMBL1486643 | 0.80 | L3MBTL1 (0.54) | CYP3A4GRM4DYRK1AMEN1KMT2A | |
| SCHEMBL4240323 | 0.80 | TP53 (0.45) | CYP3A4GRM4DYRK1AMEN1KMT2A | |
| SCHEMBL24409588 | 0.79 | MAPT (0.38) | MAOBGRM4MEN1KMT2AMAPT | |
| SCHEMBL27640403 | 0.79 | CYP3A4 (0.39) | CYP3A4GRM4DYRK1AALOX5MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093390-B2 | Substituted fused [1,2]imidazo[4,5-C] ring compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20090005371-A1 | Substituted Fused [1,2]Imidazo[4,5-C] Ring Compounds and Methods | 3M INNOVATIVE PROPERTIES COMPANY | 2009-01-01 | — | — | US | disclosed |
| EP-1845986-A2 | SUBSTITUTED FUSED [1,2]IMIDAZO[4,5-C]RING COMPOUNDS AND METHODS | Coley Pharmaceutical Group, Inc. (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006086633-A2 | SUBSTITUTED FUSED [1,2]IMIDAZO[4,5-C] RING COMPOUNDS AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005371-A1 | Substituted Fused [1,2]Imidazo[4,5-C] Ring Compounds and Methods | IL2, IFNG, IL4 | CYP3A4 257/4885MAOB 3128/4885GRM4 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.